TWI369356B - Tetrahydropyridoindole derivatives - Google Patents

Tetrahydropyridoindole derivatives

Info

Publication number: TWI369356B
Authority: TW; Taiwan
Prior art keywords: tetrahydropyridoindole derivatives; tetrahydropyridoindole; derivatives
Prior art date: 2004-03-11

Application number

TW094107583A

Other languages

English (en)

Other versions

TW200538434A (en

Inventor

Heinz Fretz

Anja Fecher

Kurt Hilpert

Markus Riederer

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-11

Filing date

2005-03-11

Publication date

2012-08-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI369356(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-03-11 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2005-12-01 Publication of TW200538434A publication Critical patent/TW200538434A/zh

2012-08-01 Application granted granted Critical

2012-08-01 Publication of TWI369356B publication Critical patent/TWI369356B/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Indole Compounds (AREA)

TW094107583A 2004-03-11 2005-03-11 Tetrahydropyridoindole derivatives TWI369356B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP2004002493		2004-03-11

Publications (2)

Publication Number	Publication Date
TW200538434A TW200538434A (en)	2005-12-01
TWI369356B true TWI369356B (en)	2012-08-01

Family

ID=34961211

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW094107583A TWI369356B (en)	2004-03-11	2005-03-11	Tetrahydropyridoindole derivatives

Country Status (24)

Country	Link
US (2)	US7714132B2 (zh)
EP (1)	EP1725553B1 (zh)
JP (1)	JP4051398B2 (zh)
KR (1)	KR100808742B1 (zh)
CN (1)	CN1930162B (zh)
AR (1)	AR047928A1 (zh)
AT (1)	ATE394399T1 (zh)
AU (1)	AU2005229356B2 (zh)
BR (1)	BRPI0508540B8 (zh)
CA (1)	CA2558509C (zh)
DE (1)	DE602005006539D1 (zh)
DK (1)	DK1725553T3 (zh)
ES (1)	ES2304010T3 (zh)
IL (1)	IL177968A0 (zh)
MY (1)	MY143795A (zh)
NO (1)	NO337996B1 (zh)
NZ (1)	NZ550365A (zh)
PL (1)	PL1725553T3 (zh)
PT (1)	PT1725553E (zh)
RU (1)	RU2387652C2 (zh)
SI (1)	SI1725553T1 (zh)
TW (1)	TWI369356B (zh)
WO (1)	WO2005095397A1 (zh)
ZA (1)	ZA200608446B (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1833791T3 (da)	2004-12-27	2011-10-24	Actelion Pharmaceuticals Ltd	2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
RU2303597C1 (ru) *	2006-05-12	2007-07-27	Иващенко Андрей Александрович	Фармацевтическая композиция, способы ее получения и применения
WO2007149312A2 (en)	2006-06-16	2007-12-27	The Trustees Of The University Of Pennsylvania	Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph
US20150072963A1 (en) *	2006-06-16	2015-03-12	The Trustees Of The University Of Pennsylvania	Compositions and methods for regulating hair growth
SI2051962T1 (sl) *	2006-08-07	2012-02-29	Actelion Pharmaceuticals Ltd	Derivati (3-amino-1,2,3,4-tetrahidro-9h-karbazol-9-il)-ocetne kisline
EP2099444A4 (en)	2006-12-14	2012-11-07	Nps Pharma Inc	USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
JP2010520864A (ja)	2007-03-09	2010-06-17	ハイポイントファーマシューティカルズ，リミティドライアビリティカンパニー	ヒドロキシステロイドデヒドロゲナーゼインヒビターとしてのインドール−及びベンズイミダゾールアミド類
RU2338745C1 (ru) *	2007-03-21	2008-11-20	Андрей Александрович Иващенко	ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
JP2011500584A (ja) *	2007-10-10	2011-01-06	ケミエテック，エルエルシ−	Ｃｒｔｈ２受容体拮抗薬としての複素環化合物
JP5666036B2 (ja) *	2008-01-25	2015-02-04	メディベイションテクノロジーズ，インコーポレイテッド	新規２，３，４，５−テトラヒドロ−１Ｈ−ピリド［４，３−ｂ］インドール化合物およびその使用方法
RU2544856C2 (ru) *	2008-01-25	2015-03-20	Сергей Олегович Бачурин	НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20110112134A1 (en) *	2008-05-16	2011-05-12	Amira Pharmaceuticals, Inc.	Tricyclic Antagonists of Prostaglandin D2 Receptors
US8501959B2 (en) *	2008-06-24	2013-08-06	Panmira Pharmaceuticals, Llc	Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
GB2465062B (en)	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
KR101275980B1 (ko) *	2009-02-24	2013-06-17	머크 캐나다 인크.	Ｃｒｔｈ２ 수용체 길항제로서의 인돌 유도체
CN102596193A (zh) *	2009-07-31	2012-07-18	潘米拉制药公司	Dp2受体拮抗的皮肤调配物
DK2558447T3 (da) *	2010-03-22	2014-11-10	Actelion Pharmaceuticals Ltd	3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazolderivater og deres anvendelse som prostaglandin d2-receptormodulatorer
EP2457900A1 (en)	2010-11-25	2012-05-30	Almirall, S.A.	New pyrazole derivatives having CRTh2 antagonistic behaviour
MY165623A (en)	2011-04-14	2018-04-18	Idorsia Pharmaceuticals Ltd	7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CN104114169A (zh)	2011-12-16	2014-10-22	阿托佩斯治疗有限公司	用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
CN105229004B (zh) *	2013-05-28	2017-05-03	阿斯利康(瑞典)有限公司	化合物
LT3119779T (lt)	2014-03-17	2018-09-10	Idorsia Pharmaceuticals Ltd	Azaindolo acto rūgšties dariniai ir jų panaudojimas kaip prostaglandino d2 receptoriaus moduliatorių
MX2016011900A (es)	2014-03-18	2016-12-05	Actelion Pharmaceuticals Ltd	Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
ES2960598T3 (es)	2014-05-08	2024-03-05	Kiora Pharmaceuticals Gmbh	Compuestos para el tratamiento de enfermedades y trastornos oftálmicos
US10092550B2 (en)	2014-10-21	2018-10-09	Ions Pharmaceutical S.À R.L.	Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en)	2014-10-21	2018-03-06	Ions Pharmaceutical S.À R.L.	Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US20180021302A1 (en)	2015-02-13	2018-01-25	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
KR20180031019A (ko)	2015-07-30	2018-03-27	더 트러스티스 오브 더 유니버시티 오브 펜실베니아	Ｐｇｄ２에 의한 모발 성장 억제에 대한 민감성의 검출을 위한 인간 ｄｐ―２ 유전자의 단일 뉴클레오티드 다형성 대립유전자
CA2993893A1 (en)	2015-09-15	2017-03-23	Idorsia Pharmaceuticals Ltd	Crystalline forms
EP3761960B1 (en) *	2018-03-09	2023-11-22	Kiora Pharmaceuticals GmbH	Ophthalmic formulation
US10954234B2 (en)	2018-06-21	2021-03-23	Genentech, Inc.	Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
KR20210008223A (ko)	2019-07-11	2021-01-21	제이투에이치바이오텍 (주)	탈모증의 치료 또는 개선을 위한 화합물 및 이들의 용도
US12129265B2 (en)	2020-07-21	2024-10-29	Ankh Life Sciences Limited	Therapeutic agents and uses thereof
CN120917021A (zh) *	2023-03-15	2025-11-07	纽脑泰智有限公司	用于预防或治疗神经退行性疾病的包含新型吡啶并吲哚衍生物化合物作为活性成分的组合物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4808608A (en) *	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
DE4118741A1 (de) *	1991-06-05	1992-12-10	Schering Ag	Neue hetaryloxy-(beta)-carboline, deren herstellung und verwendung in arzneimitteln
US5817756A (en) *	1993-09-09	1998-10-06	Scios Inc.	Pseudo- and non-peptide bradykinin receptor antagonists
EP0716661B1 (en)	1993-09-09	2000-04-05	Scios Inc.	Pseudo- and non-peptide bradykinin receptor antagonists
TR199701667T2 (xx)	1995-06-21	1999-10-21	Shionogi & Co.,Ltd.	�ift �evrimli amino t�revleri ve bu t�revleri i�eren PGD2 antogonisti.
RU2140417C1 (ru) *	1995-10-17	1999-10-27	Институт физиологически активных веществ РАН	Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения
DE69733271T2 (de)	1996-12-12	2006-01-26	Shionogi & Co., Ltd.	Kondensierte heterocyclische benzolcarbonsäureamid-derivate und diese enthaltende pgd2 antagonisten
PL191760B1 (pl)	1996-12-13	2006-06-30	Shionogi & Co	Związki, pochodne benzotiofenokarboksyamidu, związki pośrednie, kompozycja farmaceutyczna zawierająca te pochodne oraz lek do leczenia blokady nosa
CN1198649C (zh)	1998-06-03	2005-04-27	盐野义制药株式会社	用于治疗瘙痒的含pgd2受体拮抗剂的药物组合物
CA2383135C (en)	1999-08-23	2010-11-30	Hiroyuki Hirai	Method of identifying properties of substance with respect to human prostaglandin d2 receptors
US20010047027A1 (en)	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
DE60115411D1 (de)	2000-04-12	2006-01-05	Merck Frosst Canada & Co Kirkl	Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
WO2001094309A1 (en)	2000-06-02	2001-12-13	Shionogi & Co., Ltd.	Drug composition antagonistic to both pgd2/txa2 receptors
US6878522B2 (en)	2000-07-07	2005-04-12	Baiyong Li	Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US7217725B2 (en) *	2000-09-14	2007-05-15	Allergan, Inc.	Prostaglandin D2 antagonist
WO2002032892A1 (en)	2000-10-17	2002-04-25	Shionogi & Co., Ltd	Process for the preparation of pgd2 antagonist
AU2001296013A1 (en)	2000-11-01	2002-05-15	Shionogi And Co., Ltd.	Pgd2 receptor antagonistic pharmaceutical compositions
FR2821854B1 (fr)	2001-03-09	2004-07-16	Genoway	Cellules et animaux transgeniques d'etude de la polarisation de la reponse immune
WO2002094830A2 (en)	2001-05-23	2002-11-28	Merck Frosst Canada & Co.	DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
US20040185509A1 (en)	2001-07-18	2004-09-23	Francois Gervais	Eosinophil prostaglandin d2 receptor assays
US20040197834A1 (en)	2001-07-20	2004-10-07	Francois Gervais	Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors
AR038136A1 (es)	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200356D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
SE0200411D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
AU2003231513A1 (en)	2002-05-16	2003-12-02	Shionogi And Co., Ltd.	Pgd2 receptor antagonist
EP2423190A1 (en)	2002-05-16	2012-02-29	Shionogi&Co., Ltd.	Compounds Exhibiting PGD 2 Receptor Antagonism
GB2388540A (en) *	2002-05-17	2003-11-19	Bayer Ag	New use of Ramatroban
TW200307542A (en)	2002-05-30	2003-12-16	Astrazeneca Ab	Novel compounds
SE0201635D0 (sv)	2002-05-30	2002-05-30	Astrazeneca Ab	Novel compounds
SE0202241D0 (sv)	2002-07-17	2002-07-17	Astrazeneca Ab	Novel Compounds
KR20050055747A (ko)	2002-10-04	2005-06-13	밀레니엄 파머슈티컬스 인코퍼레이티드	염증 질환 치료용의 ｐｇｄ2 수용체 길항제
CA2500083A1 (en)	2002-10-21	2004-04-29	Warner-Lambert Company Llc	Tetrahydroquinoline derivatives as crth2 antagonists
EP1413306A1 (en)	2002-10-21	2004-04-28	Warner-Lambert Company LLC	Tetrahydroquinoline derivatives as CRTH2 antagonists
DE60334015D1 (de)	2002-10-30	2010-10-14	Merck Frosst Canada Ltd	Pyridopyrrolizin- und pyridoindolizinderivate
NZ541234A (en)	2002-12-20	2008-06-30	Amgen Inc	Asthma and allergic inflammation modulators
EP1435356A1 (en)	2003-01-06	2004-07-07	Warner-Lambert Company LLC	Quinoline derivatives as CRTH2 antagonists
EP1598335A4 (en)	2003-02-20	2006-04-12	Taisho Pharmaceutical Co Ltd	prostaglandin
US20060089353A1 (en)	2003-03-06	2006-04-27	Maki Iwahashi	Indole derivative compounds and drugs containing the compounds as the active ingredient
SE0301009D0 (sv)	2003-04-07	2003-04-07	Astrazeneca Ab	Novel compounds
SE0301010D0 (sv)	2003-04-07	2003-04-07	Astrazeneca Ab	Novel compounds
DE60303238T2 (de)	2003-04-25	2006-09-14	Actimis Pharmaceuticals, Inc., La Jolla	Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
CN1791577A (zh)	2003-05-20	2006-06-21	麦克弗罗斯特加拿大有限公司	氟－甲基磺酰取代的环烷并吲哚和它们作为前列腺素d2拮抗剂的用途
SE0301569D0 (sv)	2003-05-27	2003-05-27	Astrazeneca Ab	Novel compounds
CA2527773A1 (en)	2003-06-12	2004-12-23	Merck Frosst Canada Ltd.	Cycloalkanepyrrolopyridines as dp receptor antagonists
WO2005007094A2 (en)	2003-07-09	2005-01-27	Tularik Inc.	Asthma and allergic inflammation modulators
SE0302232D0 (sv)	2003-08-18	2003-08-18	Astrazeneca Ab	Novel Compounds
SA04250253B1 (ar)	2003-08-21	2009-11-10	استرازينيكا ايه بي	احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
WO2005094816A1 (en)	2004-03-11	2005-10-13	Actelion Pharmaceuticals Ltd	Indol-1-yl-acetic acid derivatives
JP5063348B2 (ja)	2004-08-26	2012-10-31	アクテリオンファーマシューティカルズリミテッド	２−スルファニル−ベンゾイミダゾール−１−イル−酢酸誘導体
DK1833791T3 (da)	2004-12-27	2011-10-24	Actelion Pharmaceuticals Ltd	2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
SI2051962T1 (sl)	2006-08-07	2012-02-29	Actelion Pharmaceuticals Ltd	Derivati (3-amino-1,2,3,4-tetrahidro-9h-karbazol-9-il)-ocetne kisline

2005
- 2005-03-07 KR KR1020067018133A patent/KR100808742B1/ko not_active Expired - Fee Related
- 2005-03-07 RU RU2006135651/04A patent/RU2387652C2/ru not_active IP Right Cessation
- 2005-03-07 EP EP05715779A patent/EP1725553B1/en not_active Expired - Lifetime
- 2005-03-07 US US10/598,777 patent/US7714132B2/en not_active Expired - Fee Related
- 2005-03-07 WO PCT/EP2005/002362 patent/WO2005095397A1/en not_active Ceased
- 2005-03-07 DE DE602005006539T patent/DE602005006539D1/de active Active
- 2005-03-07 AT AT05715779T patent/ATE394399T1/de active
- 2005-03-07 DK DK05715779T patent/DK1725553T3/da active
- 2005-03-07 SI SI200530281T patent/SI1725553T1/sl unknown
- 2005-03-07 CA CA2558509A patent/CA2558509C/en not_active Expired - Fee Related
- 2005-03-07 AU AU2005229356A patent/AU2005229356B2/en not_active Ceased
- 2005-03-07 CN CN2005800076993A patent/CN1930162B/zh not_active Expired - Fee Related
- 2005-03-07 PT PT05715779T patent/PT1725553E/pt unknown
- 2005-03-07 ES ES05715779T patent/ES2304010T3/es not_active Expired - Lifetime
- 2005-03-07 PL PL05715779T patent/PL1725553T3/pl unknown
- 2005-03-07 BR BRPI0508540A patent/BRPI0508540B8/pt not_active IP Right Cessation
- 2005-03-07 JP JP2007501238A patent/JP4051398B2/ja not_active Expired - Fee Related
- 2005-03-07 NZ NZ550365A patent/NZ550365A/en not_active IP Right Cessation
- 2005-03-09 MY MYPI20050978A patent/MY143795A/en unknown
- 2005-03-11 TW TW094107583A patent/TWI369356B/zh not_active IP Right Cessation
- 2005-03-11 AR ARP050100957A patent/AR047928A1/es active IP Right Grant
2006
- 2006-09-07 IL IL177968A patent/IL177968A0/en active IP Right Grant
- 2006-10-10 NO NO20064584A patent/NO337996B1/no not_active IP Right Cessation
- 2006-10-10 ZA ZA200608446A patent/ZA200608446B/en unknown
2010
- 2010-03-16 US US12/724,946 patent/US20100234396A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AR047928A1 (es)	2006-03-01
CN1930162A (zh)	2007-03-14
BRPI0508540B1 (pt)	2019-04-02
ATE394399T1 (de)	2008-05-15
NZ550365A (en)	2010-09-30
RU2387652C2 (ru)	2010-04-27
NO20064584L (no)	2006-10-10
KR100808742B1 (ko)	2008-02-29
DK1725553T3 (da)	2008-08-18
CN1930162B (zh)	2010-06-16
RU2006135651A (ru)	2008-04-20
CA2558509C (en)	2011-11-22
US20070191416A1 (en)	2007-08-16
JP2007526276A (ja)	2007-09-13
CA2558509A1 (en)	2005-10-13
JP4051398B2 (ja)	2008-02-20
BRPI0508540A (pt)	2007-09-18
NO337996B1 (no)	2016-07-18
EP1725553B1 (en)	2008-05-07
IL177968A0 (en)	2006-12-31
DE602005006539D1 (de)	2008-06-19
AU2005229356B2 (en)	2011-06-09
US20100234396A1 (en)	2010-09-16
SI1725553T1 (sl)	2008-08-31
ES2304010T3 (es)	2008-09-01
TW200538434A (en)	2005-12-01
BRPI0508540B8 (pt)	2021-05-25
WO2005095397A1 (en)	2005-10-13
AU2005229356A1 (en)	2005-10-13
US7714132B2 (en)	2010-05-11
KR20070029670A (ko)	2007-03-14
MY143795A (en)	2011-07-15
EP1725553A1 (en)	2006-11-29
PL1725553T3 (pl)	2008-10-31
PT1725553E (pt)	2008-07-16
ZA200608446B (en)	2008-06-25
BRPI0508540A8 (pt)	2017-12-26

Publication	Publication Date	Title
TWI369356B (en)	2012-08-01	Tetrahydropyridoindole derivatives
IL180481A0 (en)	2007-06-03	Aryl-pyridine derivatives
IL180331A0 (en)	2007-07-04	3-carbamoyl - 2 - pyridone derivative
ZA200610102B (en)	2008-08-27	Pyrrazolo-pyrimidine derivatives
EP1878727A4 (en)	2013-11-13	2-AMINOQUINAZOLINE DERIVATIVES
IL185674A0 (en)	2008-01-06	1-benzylindole-2-carboxamide derivatives
IL192092A0 (en)	2008-12-29	Aryl-isoxazolo-4-yl-oxadiazole derivatives
HUS2000022I1 (hu)	2020-07-28	Tiglien-3-on származékok
ZA200703172B (en)	2008-08-27	Imidazo-benzodiazepine derivatives
IL183140A0 (en)	2007-09-20	Substituted benzoquinolizine derivatives
IL183142A0 (en)	2007-09-20	New pyridothienopyrimidine derivatives
IL192235A0 (en)	2009-02-11	Aryl-isoxazol-4-yl-imidazole derivatives
IL182739A0 (en)	2007-07-24	Acylatednonadepsipeptides used as lysobactin derivatives
AP2074A (en)	2009-12-14	New 4-benzylidene-piperidin derivatives
IL183141A0 (en)	2007-09-20	New pyridothienopyrimidine derivatives
IL191138A0 (en)	2008-12-29	Pyrazoloisoquinoline derivatives
GB0414272D0 (en)	2004-07-28	OsK1 derivatives
IL177204A0 (en)	2006-12-10	Novel 4-benzimidazol -2-ylpyridazin -3- one derivatives
IL179444A0 (en)	2007-05-15	4-phenyl-pyrimidine-2-carbonitrile derivatives
TWI346109B (en)	2011-08-01	4-amino-5-cyanopyrimidine derivatives
IL182001A0 (en)	2007-07-04	2-acylaminothiazole derivatives
GB0511410D0 (en)	2005-07-13	Benzotrizepinone derivatives
ZA200706577B (en)	2010-02-24	Dihydroimidazothiazole derivatives
GB0405905D0 (en)	2004-04-21	Azaquinazoline derivatives
GB0422397D0 (en)	2004-11-10	3-Cyano-Quinoline derivatives

Legal Events

Date	Code	Title	Description
2022-05-01	MM4A	Annulment or lapse of patent due to non-payment of fees